Clinics and research in hepatology and gastroenterology最新文献

{"title":"The role of tumor microenvironment in lenvatinib resistance of hepatocellular carcinoma","authors":"Yao Jiang ,&nbsp;Yingchen Huang ,&nbsp;Xin Hu ,&nbsp;Guanrong Chen ,&nbsp;Ronggao Chen ,&nbsp;Xiao Xu","doi":"10.1016/j.clinre.2025.102642","DOIUrl":"10.1016/j.clinre.2025.102642","url":null,"abstract":"<div><div>In 2018, lenvatinib was approved as a first-line treatment of advanced hepatocellular carcinoma (HCC). Despite the initial success, its effectiveness in long-term clinical practice is restricted by the emergence of drug resistance. The tumor microenvironment (TME), comprised of various cellular and non-cellular components,collectively drives HCC growth, invasion, and resistance to treatment. Currently, numerous investigations have elucidated that lenvatinib exerts its influence on a multitude of targets within the TME. Moreover, many components of the TME can affect the sensitivity of lenvatinib either directly through interactions or promoting tumor immune evasion. TME plays a crucial role in the development of lenvatinib resistance (LR) in HCC. This review presents an overview on the role of the TME in LR of HCC. Furthermore, it explores therapeutic strategies targeting the TME for overcoming LR. These may improve the efficacy of lenvatinib and the prognosis of advanced HCC patients.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102642"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic organoids as a platform for liver disease modeling and the development of novel therapies","authors":"E. Luce,&nbsp;A. Messina,&nbsp;J.C. Duclos-Vallée","doi":"10.1016/j.clinre.2025.102647","DOIUrl":"10.1016/j.clinre.2025.102647","url":null,"abstract":"<div><h3>Background and aims</h3><div>Liver diseases pose a major global health burden, and progress in understanding liver pathophysiology and therapeutic development is hampered by the lack of predictive human models. Hepatic organoids (<em>i.e.</em> 3D <em>in vitro</em> structures derived from primary, progenitor, or pluripotent stem cells) offer a physiologically relevant alternative to traditional 2D cultures and animal models. This review provides a comprehensive overview of hepatic organoid systems and their translational potential.</div></div><div><h3>Methods</h3><div>We reviewed recent advances in the generation, culture, and characterization of hepatic organoids. The discussion covers the diversity of cell sources, 3D matrix-based and microfluidic culture platforms, and analytical approaches used to assess organoid structure, function, and heterogeneity. Applications in disease modeling, drug development, and regenerative therapies were also examined.</div></div><div><h3>Results</h3><div>Hepatic organoids recapitulate key liver-specific functions, including albumin secretion, CYP450 activity, and bile canaliculi formation. They have been used to model monogenic and complex liver diseases (e.g., MAFLD, viral hepatitis, cancer) and to predict patient-specific drug responses. Integration into organ-on-chip systems enhances maturation and functional fidelity. Transplantation studies in bile duct ligation and hepatotoxic injury models demonstrated functional engraftment and regeneration. Limitations persist, notably in vascularization, immune integration, and standardization, but emerging solutions such as 3D bioprinting, defined matrices, co-culture strategies, and complementary approaches like bioartificial liver (BAL) systems, are advancing organoids toward clinical applicability.</div></div><div><h3>Conclusion</h3><div>Hepatic organoids are transformative platforms in hepatology, bridging experimental modeling and personalized medicine. Their continued development promises to redefine liver disease research, precision pharmacology, and regenerative therapies.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102647"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of low HER2 expression on clinicopathological features and clinical outcomes in patients with metastatic gastric cancer","authors":"Murad Guliyev ,&nbsp;Shamkhal Safarov ,&nbsp;Murat Günaltılı ,&nbsp;Mehmet Cem Fidan ,&nbsp;Emir Çerme ,&nbsp;Gülin Alkan Şen ,&nbsp;Ahmet Emin Öztürk ,&nbsp;Nuray Kepil ,&nbsp;Özkan Alan ,&nbsp;Nebi Serkan Demirci","doi":"10.1016/j.clinre.2025.102646","DOIUrl":"10.1016/j.clinre.2025.102646","url":null,"abstract":"<div><h3>Background</h3><div>Metastatic gastric cancer (GC) is an extremely fatal malignant disease. Human epidermal growth factor receptor 2 (HER2) is an important therapeutic target in patients with HER2 overexpression or gene amplification. However, the prognostic value of HER2-low expression is still controversial. This study aims to investigate the effect of HER2 expression levels on clinicopathological characteristics and clinical outcomes in patients with metastatic GC.</div></div><div><h3>Methods</h3><div>The study included patients who had diagnosed de novo or recurrent metastatic GC from January 2011 to January 2023. We classified the patients into three categories based on their HER2 expression level: negative, low, and positive.</div></div><div><h3>Results</h3><div>The current study included 191 patients, with 99 (51.8 %) classified as HER2-negative, 42 (22.2 %) as HER2-low, and 50 (26.2 %) as HER2-positive. There were significant differences in the primary origin of gastroesophageal junction (25.3 %, 23.8 %, and 44 %), signet ring cell carcinoma (54.8 %, 44.4 %, and 16 %), mucinous cell carcinoma (40.9 %, 27.8 %, and 12 %), intestinal type histology (17.9 %, 50 %, and 48.9 %), high carcinoembryonic antigen level (34.5 %, 46.2 %, and 56.5 %), &gt;2 metastatic sites (25.3 %, 45.2 %, and 42 %), liver metastasis (33.3 %, 42.9 %, and 66 %), peritoneal metastasis (44.4 %, 28.6 %, and 20 %), and distant lymph node metastasis (53.5 %, 83.3 %, and 58 %) among the HER2-negative, HER2-low, and HER2-positive groups, respectively. The HER2-low group had similar median overall survival (OS) compared to the HER2-negative group (14.8 vs. 14.5 months, p = 0.868), however, significantly shorter median OS than the HER2-positive group (14.8 vs. 18.6 months, p = 0.024).</div></div><div><h3>Conclusions</h3><div>Our findings demonstrated that patients with HER2-low metastatic GC had different clinical and pathological features. The poorer survival rates of the HER2-low group compared to the HER2-positive group might be due to the lack of effective targeted treatments for HER2-low disease. Further research is warranted to develop specific therapeutic strategies for this subgroup.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102646"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cap pressure characterization and band ligation for a tiny duodenal angioectasia with acute feeding vessel bleeding mimicking a Dieulafoy lesion","authors":"Vincent Zimmer","doi":"10.1016/j.clinre.2025.102643","DOIUrl":"10.1016/j.clinre.2025.102643","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102643"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-22 ameliorates alcohol-associated liver fibrosis via Nrf2-ARE signaling: mechanistic insights and clinical correlations","authors":"Xiaojuan Xu ,&nbsp;Heping Zhao ,&nbsp;Jie Zhang ,&nbsp;Hongyou Yan ,&nbsp;Xing Liu ,&nbsp;Junyan Huo ,&nbsp;Lijuan Huo","doi":"10.1016/j.clinre.2025.102617","DOIUrl":"10.1016/j.clinre.2025.102617","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Alcohol-associated liver fibrosis (ALF) is a key, potentially reversible stage leading to alcohol-associated liver cirrhosis, but effective treatments are lacking. This study explored whether interleukin (IL)-22, a hepatocyte survival factor, plays an anti-fibrotic role in ALF by modulating the Nrf2-ARE antioxidant pathway.</div></div><div><h3>Methods</h3><div>IL-22 and Nrf2-ARE inhibitor, ML385, were administered to rat hepatic stellate cells (HSCs) exposed to acetaldehyde. Cell proliferation, cell cycle distribution, and Nrf2-ARE activation were investigated. An ALF mouse model was used to evaluate the effects of IL-22 and ML385 on liver function, fibrosis, and Nrf2-ARE pathway activation. The expression of IL-22 and Nrf2-ARE pathway in ALF/cirrhosis patients was also examined, along with correlations to liver function and liver fibrosis degree.</div></div><div><h3>Results</h3><div>In vitro, IL-22 upregulated the Nrf2-ARE pathway, and inhibited acetaldehyde-induced HSC proliferation and activation. In ALF mice, IL-22 promoted Nrf2-ARE pathway activation, reduced oxidative stress levels and serum transaminases, and ameliorated fibrosis. The ALF patients showed increased expression of IL-22, IL-22R1, and Nrf2-ARE pathway, positively correlating with the Child-Pugh score and fibrosis severity, suggesting a compensatory response.</div></div><div><h3>Conclusions</h3><div>IL-22 alleviates ALF by activating the Nrf2 antioxidant stress pathway, and may offer a promising therapeutic option for ALF/cirrhosis patients.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102617"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Involvement of oxidative stress, lipid dysmetabolism and gut microbiol dysbiosis in oxaliplatin-induced fatty liver disease: evidence from a tree shrew model","authors":"Yulei Lu ,&nbsp;Fei Yi ,&nbsp;Wende Chen ,&nbsp;Xinglong Tan ,&nbsp;Kezhi Li ,&nbsp;Chun Yang ,&nbsp;Youzhi Lin","doi":"10.1016/j.clinre.2025.102645","DOIUrl":"10.1016/j.clinre.2025.102645","url":null,"abstract":"<div><h3>Background</h3><div>Oxaliplatin is cornerstone treatment for colorectal cancer, yet a significant proportion of patients develop drug-induced fatty liver disease (DILI). How it induces such liver injury is poorly understood and whether the gut microbiome is involved remains unknown.</div></div><div><h3>Methods</h3><div>A male tree shrew model of oxaliplatin-induced DILI was established by six intraperitoneal injections (7 mg/kg every two weeks). During the early and late phases of liver injury, liver tissue was analyzed in terms of histopathology, oxidative stress and transcriptional profiling, while feces were subjected to microbial profiling based on 16S rRNA sequencing.</div></div><div><h3>Results</h3><div>The model recapitulated key features of DILI, including severe hepatocyte steatosis and ballooning in the early phase after the final treatment, mild hepatic steatosis with sinusoidal dilatation in the late phase, and persistent hepatic oxidative stress during both phases. Transcriptional analysis of liver tissue identified 1503 differentially expressed genes (DEGs) between oxaliplatin-treated and control animals, of which 601 DEGs differed between treated animals in the early or late phases after the final treatment of DILI. Pathway enrichment revealed significant dysregulation in oxidative stress (e.g. NDUFA12, OSR1, MPO) and lipid metabolism (e.g., LDAH, ACACB, CH25H, LIPE) genes. Gut microbiota profiling showed an increase in the relative abundance of potentially harmful bacteria (e.g., <em>Parabacteroides, Rikenella, Alistipes</em> and <em>Faecalitalea)</em> and a concurrent decrease in the abundance of anti-oxidative bacteria (e.g., <em>Lactococcus</em> and <em>Flavobacterium)</em>. Notably, abundance of several microbial genera in the gut correlated with liver expression of genes involved in oxidative stress and lipid metabolism as well as with levels of oxidative stress markers, and/or fat deposition in the liver.</div></div><div><h3>Conclusion</h3><div>Our results suggest that our tree shrew model can faithfully replicate key characteristics of oxaliplatin-induced fatty liver disease, and that such disease involves oxidative stress and lipid dysmetabolism in the liver as well as dysbiosis of microbiota in the gut.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102645"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biopsy of a hepatic small vessel neoplasm: beware of bleeding","authors":"Claire Michoud ,&nbsp;Valérie Hervieu ,&nbsp;Hélène Gimonet ,&nbsp;Jérôme Dumortier","doi":"10.1016/j.clinre.2025.102644","DOIUrl":"10.1016/j.clinre.2025.102644","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102644"},"PeriodicalIF":2.6,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends, disparities, and outcomes of drug-induced pancreatitis in the United States: A nationwide analysis (2016–2020)","authors":"Guy Loic Nguefang Tchoukeu ,&nbsp;Sarpong Boateng ,&nbsp;Joel Gabin Konlack Mekontso ,&nbsp;Yazan A Al-Ajlouni ,&nbsp;Basile Njei","doi":"10.1016/j.clinre.2025.102641","DOIUrl":"10.1016/j.clinre.2025.102641","url":null,"abstract":"<div><h3>Background</h3><div>Drug-induced pancreatitis (DIP) is an underreported etiology of acute pancreatitis. DIP risk and prevalence has increased over the years with polypharmacy. Data on affected patients in the U.S. remain limited. We aim to assess disparities and outcomes in DIP hospitalizations.</div></div><div><h3>Methods</h3><div>Retrospective study including adults diagnosed with DIP using the National Inpatient Sample (NIS) database (2016–2020). The primary outcomes were inpatient mortality, and complications. Secondary outcomes included resource utilization metrics. Descriptive statistics, linear regression, and logistic regression were performed using SAS 9.4.</div></div><div><h3>Results</h3><div>5666 patients (mean age: 56.5 years; females 53.6 %) were included. Common comorbidities were hypertension (61.3 %), hyperlipidemia (42.3 %), and diabetes (22.9 %). The mortality rate was 1.5 %, with acute kidney injury (20.6 %), Sepsis (5.0 %), ileus (3.5 %) the common complications. The Mean LOS was 5.5 days, and the mean hospital charges were $60,811.20. Compared to White, Hispanics had significant odds of DIP admission (aOR: 1.11, 95 % CI: 1.01–1.21, <em>p</em> = 0.03) and increased risk of cardiac arrest (aOR 4.34, 95 % CI 1.17–15.35, <em>p</em> = 0.02). Black patients had significantly higher odds of severe DIP (aOR 1.26, 95 % CI 1.02–1.56, <em>p</em> = 0.03) and acute kidney injury (aOR 1.29, 95 % CI 1.04–1.61, <em>p</em> = 0.02), while Asian were more likely to develop sepsis (aOR 2.10, 95 % CI 1.07–3.83, <em>p</em> = 0.02), had higher hospital charges (+$42,008, <em>p</em> = 0.039) and longer LOS (+2.5 days, <em>p</em> &lt; 0.01)..</div></div><div><h3>Conclusion</h3><div>There are significant racial disparities among patients and a substantial economic burden on healthcare systems. Multifaceted strategies and research into genetic and socioeconomic predispositions are needed to address DIP.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102641"},"PeriodicalIF":2.6,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver fibrosis evaluation in patients with psychiatric diseases","authors":"Paul Carrier ,&nbsp;Morgane Chalange ,&nbsp;Murielle Girard ,&nbsp;Aurélie Prémaud ,&nbsp;Mireille Okassa ,&nbsp;Aurélie Lacroix ,&nbsp;Marilyne Debette-Gratien ,&nbsp;Brigitte Plansont ,&nbsp;Alexandre Buisson ,&nbsp;Benjamin Calvet ,&nbsp;Céline Rigaud ,&nbsp;Jérôme Boursier ,&nbsp;Philippe Nubukpo ,&nbsp;Véronique Loustaud-Ratti","doi":"10.1016/j.clinre.2025.102636","DOIUrl":"10.1016/j.clinre.2025.102636","url":null,"abstract":"<div><div>Introduction: Mental illnesses and psychiatric disorders are public health problems, with an increasing prevalence. Life expectancy of patients is compromised by comorbid somatic illnesses, including liver diseases. Screening for liver fibrosis in this population is challenging.</div><div>Materials &amp; Methods: We assessed liver fibrosis using liver stiffness (LS) measurement by FibroScan® in a large cohort of patients with severe psychiatric disorders receiving psychotropic medications for at least two years. Liver steatosis was evaluated using the Controlled Attenuation Parameter™ (CAP).</div><div>Results: 355 patients were prospectively included. Advanced fibrosis (LS &gt;8 kPa) prevalence was 6 %. In univariate analysis, advanced fibrosis was associated with high blood pressure (<em>p</em> &lt; 0.001), high ferritin concentration (<em>p</em> = 0.028), and psychotropic drug exposure (<em>p</em> = 0.036). In multivariate analysis, high blood pressure only remained significant (<em>p</em> = 0.002). 34.9 % of patients had significant steatosis (CAP &gt;275 dB/m). In univariate analysis, steatosis was associated with sleep apnea syndrome (<em>p</em> = 0.016), past alcohol dependence (<em>p</em> = 0.013), high body mass index (BMI), type 2 diabetes (<em>p</em> = 0.003), elevated triglycerides (<em>p</em> &lt; 0.001), metabolic syndrome (<em>p</em> &lt; 0.001), metabolic dysfunction-associated liver disease (<em>p</em> &lt; 0.001), and high ferritin concentration (<em>p</em> = 0.008). In multivariable analysis, high BMI and elevated triglycerides remained significant.</div><div>Conclusion: Psychiatric patients are at risk of liver fibrosis and steatosis. Systematic screening for liver diseases should be required. Further studies are needed to determine the best strategies for prevention and treatment.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102636"},"PeriodicalIF":2.6,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anorectal physiotherapy in coloproctology: Guidelines of the french national society of coloproctology","authors":"Damien Soudan ,&nbsp;Amine Alam ,&nbsp;Gwendoline Basile ,&nbsp;Christine Bataillon ,&nbsp;Sylvie Billecocq ,&nbsp;Najima Bouta ,&nbsp;Charlène Brochard ,&nbsp;Charlotte Desprez ,&nbsp;Jean-Luc Faucheron ,&nbsp;Anne-Marie Leroi ,&nbsp;Martine Loobuyck ,&nbsp;Diane Mege ,&nbsp;Pauline Roumeguere ,&nbsp;Aurélien Venara ,&nbsp;Véronique Vitton","doi":"10.1016/j.clinre.2025.102637","DOIUrl":"10.1016/j.clinre.2025.102637","url":null,"abstract":"<div><div>Anorectal physiotherapy is a safe, effective, and commonly prescribed treatment for a wide range of functional anorectal disorders. It is usually integrated into a broader medical and surgical treatment plan. For optimal outcomes, sessions must be delivered by experienced practitioners and require active patient motivation. However, access to such expertise remains limited due to a shortage of trained professionals. A clear understanding of appropriate indications and physiotherapy modalities is essential for effective patient care coordination. Currently, no national guidelines are available in France. Therefore, the French National Society of Coloproctology (SNFCP) has developed clinical practice guidelines for the use of anorectal physiotherapy in coloproctology. A panel of 15 French experts in coloproctology conducted a systematic literature review and developed graded recommendations according to HAS guidelines. When data were lacking, expert agreements were established through a voting process.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102637"},"PeriodicalIF":2.6,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}